Drugs / Anti-SARS-CoV-2 immunoglobulin
Anti-SARS-CoV-2 immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04573855 | Dec 2020 → Feb 2021 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-SARS-CoV-2 immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04573855 ↗ |
| Modality | Protein / enzyme biologic | “anti-SARS-CoV-2 equine immunoglobulin (F(ab')2)” NCT04573855 ↗ |